These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25293518)

  • 1. EGFR inhibitors and autophagy in cancer treatment.
    Cui J; Hu YF; Feng XM; Tian T; Guo YH; Ma JW; Nan KJ; Zhang HY
    Tumour Biol; 2014 Dec; 35(12):11701-9. PubMed ID: 25293518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance 
in Lung Cancer].
    Zhang Q; Xu K
    Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):607-14. PubMed ID: 27666552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
    Wu M; Zhang P
    Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
    Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
    PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
    Yu HA; Riely GJ; Lovly CM
    Clin Cancer Res; 2014 Dec; 20(23):5898-907. PubMed ID: 25303979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
    Zhou Y; Takahashi JI; Sakurai H
    Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of autophagy enhances apoptotic cell death via epidermal growth factor receptor inhibition by canertinib in cervical cancer cells.
    Aydinlik S; Dere E; Ulukaya E
    Biochim Biophys Acta Gen Subj; 2019 May; 1863(5):903-916. PubMed ID: 30825616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of the EGFR-SQSTM1 interaction by a stapled peptide suppresses lung cancer via activating autophagy and inhibiting EGFR signaling.
    Yu JJ; Zhou DD; Cui B; Zhang C; Tan FW; Chang S; Li K; Lv XX; Zhang XW; Shang S; Xiang YJ; Chen F; Yu JM; Liu SS; Wang F; Hu ZW; Hua F
    Cancer Lett; 2020 Apr; 474():23-35. PubMed ID: 31931029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and molecular insights from dual inhibitors of EGFR and VEGFR2 as a strategy to improve the efficacy of cancer therapy.
    Budipramana K; Sangande F
    Chem Biol Drug Des; 2024 May; 103(5):e14534. PubMed ID: 38697951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
    Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
    J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined EGFR and ROCK Inhibition in Triple-negative Breast Cancer Leads to Cell Death Via Impaired Autophagic Flux.
    Rontogianni S; Iskit S; van Doorn S; Peeper DS; Altelaar M
    Mol Cell Proteomics; 2020 Feb; 19(2):261-277. PubMed ID: 31772060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Co-targeting EGFR and Autophagy Impairs Ovarian Cancer Cell Survival during Detachment from the ECM.
    Yang Z; Liu Y; Wei X; Zhou X; Gong C; Zhang T; Jin P; Xu S; Ma D; Gao Q
    Curr Cancer Drug Targets; 2015; 15(3):215-26. PubMed ID: 25619386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Third Shot at EGFR: New Opportunities in Cancer Therapy.
    Guardiola S; Varese M; Sánchez-Navarro M; Giralt E
    Trends Pharmacol Sci; 2019 Dec; 40(12):941-955. PubMed ID: 31706618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EGFR-mediated autophagy as a potential strategy for cancer therapy.
    Sooro MA; Zhang N; Zhang P
    Int J Cancer; 2018 Nov; 143(9):2116-2125. PubMed ID: 29574749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
    Wykosky J; Fenton T; Furnari F; Cavenee WK
    Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chloroquine promotes gefitinib‑induced apoptosis by inhibiting protective autophagy in cutaneous squamous cell carcinoma.
    Ou C; Liu H; Ding Z; Zhou L
    Mol Med Rep; 2019 Dec; 20(6):4855-4866. PubMed ID: 31638204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.